SequelSEC

Larimar Therapeutics, Inc. LRMR

Pharmaceutical Preparations · CIK 0001374690 · Fiscal year ends 1231

Revenue
$0
Fiscal year ended 2019-12-31
Operating income
-$23.21M
Fiscal year ended 2019-12-31
Free cash flow
-$22.78M
Fiscal year ended 2019-12-31

Larimar Therapeutics, Inc. (LRMR) reported revenue of $0 and net income of -$23.13M for the fiscal year ended 2019-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Larimar Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Larimar Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Revenue$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$23.21M-$61.12M-$53.00M-$58.22M-$73.81M-$35.53M
Net income-$23.13M-$61.37M-$52.03M-$57.88M-$74.29M-$36.48M
Research & development$20.79M$47.93M$40.84M$39.94M$54.62M$27.39M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$23.18M-$61.37M-$52.03M-$57.88M-$74.29M-$36.48M
Income tax expense$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.42M$13.19M$12.16M$18.29M$19.20M$8.14M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Larimar Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Cash & equivalents$1.01M$49.33M$40.78M$32.35M$35.60M$58.10M
Total assets$5.20M$121.76M$105.51M$131.62M$189.11M$117.52M
Current assets$4.75M$121.33M$104.92M$130.90M$188.11M$117.20M
Total liabilities$5.90M$28.49M$27.29M$9.89M$20.00M$13.08M
Current liabilities$5.90M$13.31M$7.29M$9.89M$16.54M$6.90M
Total equity incl. NCI-$694.00K$2.91M$78.22M$121.73M$169.11M$104.44M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$14.54M$20.00M$20.00M$3.18MUnavailableUnavailable
Accounts payable$3.54M$3.59M$3.02M$2.57M$7.50M$2.35M

Cash flow

Larimar Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Operating cash flow-$22.70M-$51.49M-$43.78M-$51.98MUnavailableUnavailable
Capital expenditures$83.00K$108.00K$55.00K$660.00K$595.00K$58.00K
Investing cash flow-$83.00K-$6.87M$35.65M$51.45MUnavailableUnavailable
Financing cash flow$19.40M$66.91M$16.56M-$2.72MUnavailableUnavailable
Net change in cash-$3.39M$8.55M$8.42M-$3.24M-$22.51M$22.59M
Stock-based compensation$129.00K$9.63M$8.30M$10.11M$8.58M$1.55M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Larimar Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Free cash flow-$22.78M-$51.60M-$43.84M-$52.64MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.81x9.12x14.39x13.23x11.37x16.98x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LRMR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2018-12-31

Difference 90357000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.